Daxor Corp
DXR- Exchange
- Nasdaq
- SEC CIK
- 0000027367
No open-market purchases or sales by Daxor Corp insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.33M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 15
- 13F valueReported value at the end of Q2 2026
- $4.33M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding DXR, Q2 2026
No superinvestor reported holding DXR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Daxor Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 10, 2026 (view filing) | Apr 8 | 2 days | Feldschuh Michael RichardChief Executive Officer | PPurchaseDaxor Common Stock | +1.00K | $9.07 | +$9.07K | +0.5%213.7K after | |
| Mar 31, 2026 (view filing) | Mar 31 | Same day | Michel Robert JChief Financial Officer | PPurchaseDaxor Common Stock | +1.00K | $9.90 | +$9.90K | +5.0%21.1K after | |
| Mar 24, 2026 (view filing) | Mar 20 | 4 days | Jefferies JohnChief Medical Officer | PPurchaseDaxor Common Stock | +5.94K | $0.00 | $0 | +33.7%23.6K after | 2 lots |
| Dec 11, 2025 (view filing) | Dec 9 | 2 days | Michel Robert JChief Financial Officer | PPurchaseDaxor Common Stock | +3.00K | $0.00 | $0 | +17.6%20.1K after | |
| Dec 11, 2025 (view filing) | Dec 9 | 2 days | Feldschuh Jonathan AdamChief Scientific Officer | PPurchaseDaxor Common Stock | +18.0K | $0.00 | $0 | +50.1%53.9K after | |
| Nov 14, 2025 (view filing) | Nov 12 | 2 days | Jefferies JohnChief Medical Officer | PPurchaseDaxor Common Stock | +2.34K | $0.00 | $0 | +15.3%17.6K after | |
| Apr 7, 2025 (view filing) | Apr 4 | 3 days | Feldschuh Michael RichardChief Executive Officer | PPurchaseDaxor Common Stock | +2.06K | $7.89 | +$16.3K | +1.0%212.7K after | |
| Mar 27, 2025 (view filing) | Mar 26, 2024 | 366 daysLate | Feldschuh Michael RichardChief Executive Office | PPurchaseDaxor Common Stock | +1.00K | $8.13 | +$8.13K | +0.5%210.6K after | |
| Mar 20, 2025 (view filing) | Mar 10, 2024 | 375 days | Feldschuh Michael RichardChief Executive Officer | PPurchaseDaxor Common Stock | +1.49K | $7.72 | +$11.5K | +0.7%209.0K after | Amended |
| Mar 20, 2025 (view filing) | Mar 19, 2024 | 366 daysLate | Feldschuh Michael RichardChief Executive Officer | PPurchaseDaxor Common Stock | +647 | $8.15 | +$5.27K | +0.3%209.6K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Daxor Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Thompson Siegel & Walmsley LLC | 241,767 | $2.49M | 0.04% | +9,647+4.2% | Added |
| Vanguard Capital Management LLC | 48,831 | $495.6K | 0.00% | +551+1.1% | Added |
| Aristides Capital LLC | 41,689 | $429.2K | 0.11% | −30.0% | Reduced |
| Renaissance Technologies LLC | 29,421 | $302.9K | 0.00% | +1,410+5.0% | Added |
| Susquehanna International Group, LLP | 27,131 | $275.4K | 0.00% | +13,411+97.7% | Added |
| Nano Cap New Millennium Growth Fund L P | 12,500 | $128.7K | 0.10% | 00.0% | Unchanged |
| Crescent Grove Advisors, LLC | 12,423 | $127.9K | 0.01% | +1,700+15.9% | Added |
| SBI Securities Co., Ltd. | 3,131 | $32.2K | 0.00% | +3+0.1% | Added |
| Morgan Stanley | 3,087 | $31.8K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 1,037 | $10.5K | 0.00% | 00.0% | Unchanged |